Indian researchers, in collaboration with Bharat Biotech and Washington University in St. Louis, have developed an innovative nasal vaccine for COVID-19 called iNCOVACC. This groundbreaking vaccine, which is administered through the nose, has received emergency use approval in India for both primaryRead more
Indian researchers, in collaboration with Bharat Biotech and Washington University in St. Louis, have developed an innovative nasal vaccine for COVID-19 called iNCOVACC. This groundbreaking vaccine, which is administered through the nose, has received emergency use approval in India for both primary vaccination and as a booster. Unlike traditional injectable vaccines, the nasal vaccine aims to block the virus right at its entry point in the nasal passages and upper respiratory tract, potentially preventing infection and breaking the transmission cycle.
The nasal vaccine’s ability to trigger a strong immune response directly where the virus enters the body is a significant advantage. This could not only prevent severe disease but also reduce the spread of the virus, which is a crucial aspect that injectable vaccines have struggled with. Moreover, the nasal vaccine is easier to administer, as it doesn’t require needles, making it more accessible and less intimidating, especially for those who fear injections.
This new approach could revolutionize the global fight against COVID-19 and other respiratory illnesses. By focusing on mucosal immunity, the vaccine may be more effective in stopping the virus from spreading, thus playing a vital role in controlling the pandemic and preparing for future outbreaks. Additionally, the vaccine is designed to be cost-effective and easy to store, making it particularly suitable for use in low- and middle-income countries.
See less
The following are some of the main obstacles that the Indian biotechnology sector must overcome: - Poor research quality: research articles are written with the mindset of "publish or perish," where quantity matters more than quality. - Low funding: the majority of biotechnology research in India isRead more
The following are some of the main obstacles that the Indian biotechnology sector must overcome:
See less– Poor research quality: research articles are written with the mindset of “publish or perish,” where quantity matters more than quality.
– Low funding: the majority of biotechnology research in India is supported by public funds; – Low scientist earnings: in comparison to wealthy nations, scientist wages are lower
– Obtaining ethical and regulatory clearance: a time-consuming, costly procedure
– Specialised work: in the biotechnology industry, most positions are occupied by knowledgeable and experienced scientists, which leaves less space for less experienced and younger scientists.
Here are a few strategies for overcoming these obstacles :
Boost applied research financing from the corporate sector; Promote product development and innovation; and Connect academic institutions with business to provide scientists the chance to launch their own ventures.
Adopt laws enabling scientists to leave academic institutions and research centres to work in industry. Boost the biotech industry by utilising big data and artificial intelligence.